Adaptive Biotechnologies Corporation

HDT Bio Corp is a Seattle-based company focused on developing transformative technologies in the biosciences sector. The company is committed to fostering partnerships with investors and collaborators who share their vision of impactful innovation. With a dedicated team of scientists and business professionals, HDT Bio prides itself on a collaborative work environment that embraces both successes and challenges. The company actively seeks enthusiastic individuals to join their mission and contribute to their ongoing projects. Generated from the website

Umoja Biopharma, Inc., based in Seattle, WA, is a pioneering biotechnology company focused on developing innovative in vivo chimeric antigen receptor (CAR) T cell therapies aimed at improving cancer treatments. Their flagship VivoVec platform generates CAR T cells directly within a patient's body, eliminating the typical wait times associated with traditional ex vivo therapies. With a commitment to advancing cancer care, Umoja has established its own in-house manufacturing capabilities to ensure reliable production and quality control of its therapeutics. The company's pipeline is dedicated to the treatment of various cancers, with potential applications for other conditions, reflecting its mission to enhance patient treatment experiences. Generated from the website

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. Through science and technology, the company strives to develop and commercialize products that address unmet medical needs, improve survival and have a favorable safety profile. Additionally, Dendreon develops therapeutic vaccines that stimulate the body's immune system to help fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. The company also develops vaccines to treat breast, colorectal, lung, ovarian and uterine cancers along with monoclonal antibodies to fight blood cancers, such as non-Hodgkin's and B-cell lymphomas. Its partners include Japan's Kirin Brewery and Genentech. Dendreon Corporation is located in Seattle.